Achillion Pharmaceuticals (ACHN) Reports Positive Phase 2a Clinical Results for Hepatitis C Treatment
Achillion Pharmaceuticals Inc., an innovative pharmaceutical focused on solutions against infectious disease including hepatitis C and resistant bacterial infections, today announced top-line results from its on-going phase 2a clinical trial of ACH-1625 dosed once daily in combination with Pegasys(R) and Copegus(R) a current standard of care (SOC) in patients with chronic hepatitis C (HCV) infection. The first of a two-segment phase 2a trial involved 64 patients administered three doses of ACH-1625 or placebo with peginterferon alfa-2a and ribavirin, dosed for a four-week study. The analysis demonstrated that 75-81 percent of patients receiving ACH-1625 achieved rapid virologic response (RVR) with a…